Compare Summit Therapeutics Inc (SMMT) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs T-Mobile Us Inc — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while T-Mobile Us Inc trades at $190.25 (market cap $211.72B). The key difference: T-Mobile Us Inc is far larger — about 20.2× Summit Therapeutics Inc's market cap, and T-Mobile Us Inc pays a 2.09% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TMUS | |
|---|---|---|
Market Cap | $10.48B | $211.72B |
Sector | Health | Media |
52-Week High | $29.32 | $259.01 |
52-Week Low | $13.05 | $167.65 |
Enterprise Value | $9.90B | $329.42B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
T-Mobile (TMUS) trades at $190.64, down 0.93% on the day, with strong technical momentum showing a bullish moving average signal despite overbought RSI readings near 85. The company demonstrates robust fundamentals with 2025 revenue of $88.31 billion and net income of $10.99 billion, though profit margins have moderated from 13.92% in 2024 to 12.44% in 2025. Recent earnings show mixed results with Q1 2026 beating expectations while Q4 2025 missed, with Q2 2026 results pending.
T-Mobile presents a compelling growth story in telecom with strong analyst support (83% buy ratings) and a $237.40 consensus price target implying 25% upside. Key risks include increasing debt-to-asset ratios (39.35% in 2025) and competitive pressures from satellite internet providers. The stock's current valuation at 20.79 P/E appears reasonable given growth prospects, though investors should monitor execution on subscriber and broadband growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
